Innate Pharma S.A. (IPHA) News
NASDAQ: IPHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IPHA news summary
We found 4 recent headlines mentioning Innate Pharma S.A. (IPHA): 1 in the past week and 4 in the past 30 days, most often from Nasdaq, Business Wire. IPHA is making an outsized move today, down 8.14% at $0.8634, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Innate Pharma S.A. Presents Initial Phase 1 Clinical Data for IPH4502", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Innate Pharma S.A. headlines
- Innate Pharma S.A. Presents Initial Phase 1 Clinical Data for IPH4502Innate Pharma S.A. announced initial Phase 1 clinical data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate incorporating an exatecan payload, in…Nasdaq
- Innate Pharma S.A. to Host Event on IPH4502 on November 18, 2026Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC.…Nasdaq
- Innate Pharma Reports Third Quarter 2026 Business and Financial UpdateMARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine…Business Wire
- Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027Innate Pharma S.A. announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026…Nasdaq